PHARMACY

Investors file suit against Biovail after delay in release of Aplenzin

BY Alaric DeArment

NEW YORK In a class-action suit filed in a district court Thursday, a Canadian drug maker is accused of making misleading statements about an anti-depressant drug as the Food and Drug Administration reviewed it for approval.

A group of American investors filed the suit against Biovail in the United States District Court for the Southern District of New York, alleging that it failed to disclose that the drug Aplenzin (bupropion hydrobromide) had not met certain FDA conditions for approval, thus delaying its entering the market. The FDA ultimately approved the drug in April.

Canada’s largest publicly traded drug company, Biovail is headquartered in Mississauga, Ontario.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Zebra to provide industry printer services to Managed Healthcare Associates

BY Alaric DeArment

VERNON HILLS, Pa. A company that provides printing services for the healthcare industry and the country’s largest alternate-site GPO have signed a three-year agreement to provide barcode and card printers.

Zebra Technologies will provide Managed Healthcare Associates with its printers, as well as supplies and service agreements, at almost 500 of MHA’s member facilities for identification, tracking and access-control applications.

“Increasing patient safety is among the highest priorities in healthcare today,” MHA contract coordinator Kelly Decker said. “Having effective information technology in place is a key step in building a culture of safety that enables providers to improve outcomes and quality of care throughout their organizations.”

According to the Institute of Medicine, at least 1.5 million preventable adverse drug events happen every year in the United States, thought bar coding has been shown to reduce dangerous and expensive medical errors.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Drug adherence study shows that patients suffering despression often go off medication

BY Alaric DeArment

NEW YORK A company that provides patient adherence and education programs released a study recently that examined adherence rates among patients on SSRI/SNRI antidepressant therapy.

The study, by Burlington, Mass.-based Adheris, found that patients new to antidepressant treatment and those who had restarted therapy after a lapse of six months or more were twice as likely to discontinue therapy in the first 30 days of treatment versus patients previously dispensed an antidepressant.

It also found that the greatest differences in the duration of antidepressant use were not among patients using different drugs, but among patients taking the same drug with different levels of prior experience with antidepressants.

The study appears in the September issue of the journal Clinical Therapeutics. It included more than 211,000 patients taking SSRI/SNRIs from 1,157 retail pharmacies across the country.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?